KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Zusammenfassung

VOLUME 107 | ISSUE 2S | FEBRUARY 2025 www.kidney-international.org SUPPLEMENT TO KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) KDIGO 2025 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION, MANAGEMENT, AND TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) Kidney International(2025)107(Suppl 2S), S1–S239S1 KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Trea

Kerninformationen

es (PROMs) in ADPKD care S238Appendix 2: Recommended checklist of issues to discuss at the beginning of the patient journey S239Appendix 3: Patient organizations dealing with ADPKD or kidney disease in general, and other useful resources for patients and healthcare providers This article is publishe...

n use of common lifestyle products in people with ADPKD S165Table 20. Key concerns of people with ADPKD and their family members, relating to psychosocial issues S50Table 21. Definitions of phenotypical entities in children with ADPKD S192Table 22. Clinical questions and SR topics in PICOD format S2...

ses S80Figure 9. The Mayo Imaging Classification (MIC) of autosomal dominant polycystic kidney disease (ADPKD; left panel) with examples (right panel) of (a,b) MIC subclass 1A and 1E, (c–f) MIC subclass 2A, and (g,h) MIC subclass 2B www.kidney-international.orgcontents Kidney International(2025)10...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen